{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:40:49Z","timestamp":1790138449473,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bjid.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T19:20:16Z","timestamp":1576005616000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV\/AIDS"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-6091","authenticated-orcid":false,"given":"Larissa Negromonte","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-8840","authenticated-orcid":false,"given":"Ricardo Arraes de Alencar","family":"Ximenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyana","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-5693","authenticated-orcid":false,"given":"Ulisses Ramos","family":"Montarroyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2537-1476","authenticated-orcid":false,"given":"Dem\u00f3crito de Barros","family":"Miranda-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2019.11.002_bib0005","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Programa Nacional de DST e Aids. Recomenda\u00e7\u00f5es para Terapia Anti-retroviral em Adultos Infectados pelo HIV: 2008. 7a Ed. - Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2008. Available from: www.aids.gov.br\/pt-br\/pub\/2007\/recomendacoes-para-terapia antirretroviral-em-adultos-infectados-pelo-hiv-2008. Acessed in: Nov. 2015."},{"key":"10.1016\/j.bjid.2019.11.002_bib0010","unstructured":"Minist\u00e9rio da Sa\u00fade. Protocolo cl\u00ednico e diretrizes terap\u00eauticas para manejo da infec\u00e7ao pelo HIV em adultos. 2013; 216. Available from: www.aids.gov.br\/pagina\/publicacoes. Acessed in: Nov. 2015."},{"issue":"2","key":"10.1016\/j.bjid.2019.11.002_bib0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1468-1293.2009.00750.x","article-title":"Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral- na\u00efve patients","volume":"11","author":"Cicconi","year":"2010","journal-title":"HIV Med."},{"key":"10.1016\/j.bjid.2019.11.002_bib0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2334-12-296","article-title":"Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study","volume":"12","author":"Prosperi","year":"2012","journal-title":"BMC Infect Dis."},{"issue":"1","key":"10.1016\/j.bjid.2019.11.002_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1590\/S1413-86702007000100007","article-title":"Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil","volume":"11","author":"de P\u00e1dua","year":"2007","journal-title":"Braz J Infect Dis."},{"issue":"1","key":"10.1016\/j.bjid.2019.11.002_bib0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bjid.2013.04.005","article-title":"Incidence rate of modifying or discontinuing first combined antiretroviral therapy regimen due to toxicity during the first year of treatment stratified by age","volume":"18","author":"Torres","year":"2014","journal-title":"Brazilian J Infect Dis."},{"issue":"8","key":"10.1016\/j.bjid.2019.11.002_bib0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/aid.2009.0274","article-title":"Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil","volume":"26","author":"Cardoso","year":"2010","journal-title":"AIDS Res Hum Retroviruses."},{"key":"10.1016\/j.bjid.2019.11.002_bib0040","series-title":"Global Report: UNAIDS report on the global AIDS epidemic 2013. Unaids","first-page":"198","author":"Unaids","year":"2013"},{"key":"10.1016\/j.bjid.2019.11.002_bib0045","series-title":"Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST, Aids e HIV. Boletim Epidemiol\u00f3gico AIDS e DST","author":"Minist\u00e9rio da Sa\u00fade","year":"2016"},{"issue":"6","key":"10.1016\/j.bjid.2019.11.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010490","article-title":"Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America","volume":"5","author":"Cesar","year":"2010","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.bjid.2019.11.002_bib0055","first-page":"263","article-title":"Discontinuation of Initial Antiretroviral Therapy in Clinical Practice : Moving Toward Individualized Therapy","volume":"71","author":"Di Biagio","year":"2016","journal-title":"JAIDS."},{"issue":"15","key":"10.1016\/j.bjid.2019.11.002_bib0060","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/QAD.0b013e32835722bd","article-title":"Could better tolerated HIV drug regimens improve patient outcome?","volume":"26","author":"Smit","year":"2012","journal-title":"Aids"},{"issue":"2","key":"10.1016\/j.bjid.2019.11.002_bib0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1590\/S0104-42302012000200019","article-title":"Fatores determinantes para modifica\u00e7\u00f5es da terapia antirretroviral inicial","volume":"58","author":"Lima","year":"2012","journal-title":"Rev Assoc Med Bras."},{"key":"10.1016\/j.bjid.2019.11.002_bib0070","series-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO Guidel","author":"WHO","year":"2013"},{"issue":"4","key":"10.1016\/j.bjid.2019.11.002_bib0075","first-page":"422","article-title":"Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy : a systematic review and meta-analysis of randomized trials","volume":"69","author":"Ford","year":"2015","journal-title":"JAIDS."},{"issue":"8","key":"10.1016\/j.bjid.2019.11.002_bib0080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/521150","article-title":"Adverse effects of highly active antiretroviral therapy in developing countries","volume":"45","author":"Subbaraman","year":"2007","journal-title":"Clin Infect Dis."},{"issue":"September","key":"10.1016\/j.bjid.2019.11.002_bib0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.11599\/germs.2015.1075","article-title":"Original article Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz","volume":"5","author":"Abah","year":"2015","journal-title":"GERMS."},{"key":"10.1016\/j.bjid.2019.11.002_bib0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","article-title":"Understanding and managing the adverse effects of antiretroviral therapy","volume":"85","author":"Hawkins","year":"2010","journal-title":"Antiviral Res."},{"issue":"9","key":"10.1016\/j.bjid.2019.11.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203530","article-title":"Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: observational study in two South African cohorts","volume":"13","author":"de Waal","year":"2018","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bjid.2019.11.002_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091028","article-title":"Influence of adverse drug reactions on treatment success: Prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India","volume":"9","author":"Shet","year":"2014","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.bjid.2019.11.002_bib0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1310\/hct1506-231","article-title":"Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-na\u00efve HIV-1 patients: meta-analysis of randomized clinical studies","volume":"15","author":"Winston","year":"2014","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.bjid.2019.11.002_bib0110","unstructured":"Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Nota informativa complementar 019\/2017. 2017."},{"key":"10.1016\/j.bjid.2019.11.002_bib0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Medicine"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867019304842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867019304842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:55:38Z","timestamp":1761407738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867019304842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1413867019304842"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2019.11.002","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV\/AIDS","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}